TY  - CHAP
M1  - Book, Section
TI  - Risk Assessment and Clinical Management – Uterine Cancer
A1  - Zeybek, Burak
A1  - Soble, Whitney
A1  - Ratner, Elena
A2  - Llor, Xavier
A2  - Hofstatter, Erin Wysong
Y1  - 2022
N1  - 
T2  - Cancer Genetics: A Clinical Approach
AB  - Uterine  cancer  is  the  most  common  gynecologic  malignancy  in  the  United  States,  with  an  estimated  63,230  new  cases  and  11,350  deaths  from  the  disease  every  year.1  Based  on  the  data  from  its  national  cancer  database,  and  Surveillance,  Epidemiology  and  End  Results  (SEER),  the  lifetime  risk  of  endometrial  cancer  is  2.8%  and  the  average  age  at  diagnosis  is  62.2  As  opposed  to  ovarian  malignancies,  the  majority  of  the  cases  are  diagnosed  at  an  early  stage  (67%  at  stage  I),  as  more  than  90%  of  women  with  uterine  cancer  have  an  early  presenting  symptom  (abnormal  uterine  bleeding).3  The  most  common  histologic  subtype  is  adenocarcinoma  of  the  endometrium,  which  is  subcategorized  into  two  distinct  groups  that  differ  in  incidence,  response  to  therapy  and  prognosis.4  Type  I  tumors  (80%  of  endometrial  carcinomas),  have  more  favorable  outcomes  due  to  grade  1  or  2  endometrioid  histology,  early  stage  at  diagnosis,  retention  of  hormone  receptor  status  and  younger  age  at  onset.  On  the  other  hand,  type  II  tumors  (20%  of  endometrial  cancers)  portend  a  poorer  prognosis,  as  these  represent  grade  3  endometrioid  tumors  and  tumors  of  non-endometrioid  histology  such  as  serous,  clear  cell,  mucinous,  squamous,  transitional  cell,  mesonephric  and  undifferentiated.  They  often  lack  hormone  receptors  and  there  is  no  clear  association  with  estrogen  stimulation.  
SN  - 
PB  - McGraw Hill
CY  - New York, NY
Y2  - 2024/04/25
UR  - hemonc.mhmedical.com/content.aspx?aid=1182365721
ER  -